Our Publications

  • Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery. Lanahan, C.R., Kelly, B.N., Gadd, M.A. et al. Breast Cancer Res Treat (2021). https://doi.org/10.1007/s10549-021-06106-w
  • Feasibility Study of a Novel Protease-Activated Fluorescent Imaging System for Real-Time, Intraoperative Detection of Residual Breast Cancer in Breast Conserving Surgery. Smith, B.L., Lanahan, C.R., Specht, M.C. et al. Ann Surg Oncol 27, 1854–1861 (2020). https://doi.org/10.1245/s10434-019-08158-1
  • A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Whitley, M.J.; Cardona, D.M.; Lazarides, A.L. et al. Science Translational Medicine 06 Jan 2016: Vol. 8, Issue 320, pp. 320ra4 DOI:10.1126/scitranslmed.aad0293
  • Imaging primary mouse sarcomas after radiation therapy using cathepsin-activatable fluorescent imaging agents. Cuneo KC, Mito JK, Javid MP et Al. Int J Radiat Oncol Biol Phys. 2013 May 1; 86(1):136-42. doi: 10.1016/j.ijrobp.2012.12.007. Epub 2013 Feb 4.
  • A novel imaging system permits real-time in vivo tumor bed assessment after resection of naturally occurring sarcomas in dogs. Eward WC, Mito JK, Eward CA, Carter JE, Ferrer JM, Kirsch DG, Brigman BE. Clin Orthop Relat Res. 2013 Mar; 471(3):834-42. doi: 10.1007/s11999-012-2560-8.
  • Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Mito JK, Ferrer JM, Brigman BE, Lee CL, Dodd RD, Eward WC, Marshall LF, Cuneo KC, Carter JE, Ramasunder S, Kim Y, Lee WD, Griffith LG, Bawendi MG, Kirsch DG. Cancer. 2012 Nov 1; 118(21):5320-30. doi: 10.1002/cncr.27458. Epub 2012 Mar 21.

Pipeline

Cancer Awareness